CR20200549A - Constructos de fusión de anticuerpos que se acoplan a células nk - Google Patents
Constructos de fusión de anticuerpos que se acoplan a células nkInfo
- Publication number
- CR20200549A CR20200549A CR20200549A CR20200549A CR20200549A CR 20200549 A CR20200549 A CR 20200549A CR 20200549 A CR20200549 A CR 20200549A CR 20200549 A CR20200549 A CR 20200549A CR 20200549 A CR20200549 A CR 20200549A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antigen
- cd16a
- binding
- antibody fusion
- fusion constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>La invención se refiere a proteínas multiespecíficas de unión al antígeno que se acoplan a células <em>natural killer</em> (NK) para desencadenar la citotoxicidad de células NK al acoplarse al CD16A (FcgRIIIA) expresado en células NK, en donde la proteína de unión al antígeno comprende al menos dos porciones de unión al antígeno CD16A y al menos una porción de unión al antígeno diana adicional. La porción de unión al antígeno CD16A comprende regiones variables de la cadena liviana y cadena pesada ligadas una después de la otra en una cadena de polipéptido y la región variable en el terminal N de la cadena de polipéptido que comprende la porción de unión al antígeno CD16A es una región variable de la cadena liviana</p>
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167385 | 2018-04-13 | ||
| EP18167384 | 2018-04-13 | ||
| EP18190661 | 2018-08-24 | ||
| EP18190662 | 2018-08-24 | ||
| PCT/IB2019/053040 WO2019198051A2 (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200549A true CR20200549A (es) | 2021-03-18 |
Family
ID=66625219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200549A CR20200549A (es) | 2018-04-13 | 2019-04-12 | Constructos de fusión de anticuerpos que se acoplan a células nk |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11001633B2 (es) |
| EP (1) | EP3774914A2 (es) |
| JP (2) | JP2021521275A (es) |
| KR (1) | KR20200143436A (es) |
| CN (3) | CN113880952A (es) |
| AU (2) | AU2019252970A1 (es) |
| BR (1) | BR112020020828A2 (es) |
| CA (1) | CA3095373A1 (es) |
| CL (2) | CL2020002625A1 (es) |
| CO (1) | CO2020014167A2 (es) |
| CR (1) | CR20200549A (es) |
| IL (1) | IL277925A (es) |
| MA (1) | MA52227A (es) |
| MX (1) | MX2020010728A (es) |
| PE (1) | PE20201346A1 (es) |
| PH (1) | PH12020551664B1 (es) |
| RU (1) | RU2022105827A (es) |
| SG (1) | SG11202010064QA (es) |
| TW (1) | TW202012441A (es) |
| WO (1) | WO2019198051A2 (es) |
| ZA (1) | ZA202006325B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115066274A (zh) * | 2019-09-25 | 2022-09-16 | 斯图加特大学 | 三价结合分子 |
| EP4073117A1 (en) * | 2019-12-10 | 2022-10-19 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
| GB201919058D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| AU2020414409A1 (en) | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| JP7620780B2 (ja) * | 2020-06-30 | 2025-01-24 | ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| WO2022098972A1 (en) * | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| US20250277024A1 (en) * | 2020-12-03 | 2025-09-04 | Amgen Inc. | Molecules with multiple binding domains |
| JP2024503933A (ja) * | 2021-01-27 | 2024-01-29 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | Ｃｄ１６ａに対する単一ドメイン抗体およびその使用 |
| WO2022232503A1 (en) | 2021-04-30 | 2022-11-03 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| JP2024529494A (ja) * | 2021-07-30 | 2024-08-06 | クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド | 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用 |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| EP4405379A4 (en) * | 2021-09-24 | 2025-08-20 | Synergy Imt Inc | COMPOSITION OF RECOMBINANT ANTIGEN-BINDING MOLECULES AND METHOD OF MANUFACTURE AND USE THEREOF |
| US20260070986A1 (en) | 2021-11-03 | 2026-03-12 | Affimed Gmbh | Bispecific cd16a binders |
| IL312515A (en) | 2021-11-03 | 2024-07-01 | Affimed Gmbh | Bispecific cd16a binders |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| CN114349869B (zh) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | 一种双特异性的nk细胞激动剂及制备方法和应用 |
| CN119923415A (zh) * | 2022-08-05 | 2025-05-02 | 成都恩沐生物科技有限公司 | 靶向可二聚化肿瘤抗原和免疫刺激性抗原的多特异性抗体 |
| CN120035609A (zh) * | 2022-09-14 | 2025-05-23 | 大塚制药株式会社 | Pd-1激动剂抗体 |
| CN120641128A (zh) * | 2023-02-06 | 2025-09-12 | 乐普创一生物科技（上海）有限公司 | 抗cd16a抗体及其用途 |
| KR20240136856A (ko) * | 2023-03-06 | 2024-09-19 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-cd16 항체 및 이의 용도 |
| WO2025257588A1 (en) * | 2024-06-10 | 2025-12-18 | Affimed Gmbh | Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| EP2361936B1 (en) * | 2010-02-25 | 2016-04-20 | Affimed GmbH | Antigen-binding molecule and uses thereof |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2825557B1 (en) | 2012-03-16 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Soluble engineered monomeric fc |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| JP2016514676A (ja) * | 2013-03-15 | 2016-05-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 四価二重特異性抗体 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| RU2016132863A (ru) * | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| CA3138083A1 (en) * | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| LT3292153T (lt) * | 2015-05-04 | 2019-11-11 | Affimed Gmbh | Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai |
| EP3091031A1 (en) * | 2015-05-04 | 2016-11-09 | Affimed GmbH | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| WO2018158349A1 (en) * | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
-
2019
- 2019-04-12 CA CA3095373A patent/CA3095373A1/en active Pending
- 2019-04-12 CR CR20200549A patent/CR20200549A/es unknown
- 2019-04-12 KR KR1020207032435A patent/KR20200143436A/ko not_active Ceased
- 2019-04-12 PH PH1/2020/551664A patent/PH12020551664B1/en unknown
- 2019-04-12 JP JP2021504593A patent/JP2021521275A/ja active Pending
- 2019-04-12 AU AU2019252970A patent/AU2019252970A1/en not_active Abandoned
- 2019-04-12 MA MA052227A patent/MA52227A/fr unknown
- 2019-04-12 CN CN202111125559.3A patent/CN113880952A/zh active Pending
- 2019-04-12 MX MX2020010728A patent/MX2020010728A/es unknown
- 2019-04-12 EP EP19725409.7A patent/EP3774914A2/en active Pending
- 2019-04-12 WO PCT/IB2019/053040 patent/WO2019198051A2/en not_active Ceased
- 2019-04-12 CN CN202111125475.XA patent/CN113817066A/zh active Pending
- 2019-04-12 SG SG11202010064QA patent/SG11202010064QA/en unknown
- 2019-04-12 CN CN201980033176.8A patent/CN112119097B/zh active Active
- 2019-04-12 RU RU2022105827A patent/RU2022105827A/ru unknown
- 2019-04-12 PE PE2020001584A patent/PE20201346A1/es unknown
- 2019-04-12 BR BR112020020828-0A patent/BR112020020828A2/pt unknown
- 2019-04-15 TW TW108113068A patent/TW202012441A/zh unknown
- 2019-12-13 US US16/714,396 patent/US11001633B2/en active Active
-
2020
- 2020-10-09 CL CL2020002625A patent/CL2020002625A1/es unknown
- 2020-10-11 IL IL277925A patent/IL277925A/en unknown
- 2020-10-12 ZA ZA2020/06325A patent/ZA202006325B/en unknown
- 2020-11-12 CO CONC2020/0014167A patent/CO2020014167A2/es unknown
-
2021
- 2021-04-20 US US17/235,854 patent/US20210253698A1/en not_active Abandoned
-
2023
- 2023-04-14 CL CL2023001085A patent/CL2023001085A1/es unknown
-
2024
- 2024-04-17 US US18/637,556 patent/US20240294647A1/en active Pending
-
2025
- 2025-01-17 JP JP2025006634A patent/JP2025081307A/ja active Pending
-
2026
- 2026-01-27 AU AU2026200541A patent/AU2026200541A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020014167A2 (es) | 2021-04-08 |
| WO2019198051A3 (en) | 2019-11-14 |
| PH12020551664A1 (en) | 2021-12-13 |
| CN113880952A (zh) | 2022-01-04 |
| ZA202006325B (en) | 2025-12-17 |
| US20210253698A1 (en) | 2021-08-19 |
| SG11202010064QA (en) | 2020-11-27 |
| MX2020010728A (es) | 2020-11-06 |
| AU2026200541A1 (en) | 2026-02-19 |
| CA3095373A1 (en) | 2019-10-17 |
| BR112020020828A2 (pt) | 2021-01-19 |
| AU2019252970A1 (en) | 2020-11-26 |
| CN112119097B (zh) | 2021-10-15 |
| PH12020551664B1 (en) | 2023-05-19 |
| WO2019198051A2 (en) | 2019-10-17 |
| CL2023001085A1 (es) | 2023-10-06 |
| US20240294647A1 (en) | 2024-09-05 |
| US11001633B2 (en) | 2021-05-11 |
| MA52227A (fr) | 2021-04-21 |
| CN113817066A (zh) | 2021-12-21 |
| RU2022105827A (ru) | 2022-04-05 |
| CL2020002625A1 (es) | 2021-02-19 |
| KR20200143436A (ko) | 2020-12-23 |
| JP2025081307A (ja) | 2025-05-27 |
| JP2021521275A (ja) | 2021-08-26 |
| IL277925A (en) | 2020-11-30 |
| US20200109202A1 (en) | 2020-04-09 |
| TW202012441A (zh) | 2020-04-01 |
| PE20201346A1 (es) | 2020-11-25 |
| EP3774914A2 (en) | 2021-02-17 |
| CN112119097A (zh) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200549A (es) | Constructos de fusión de anticuerpos que se acoplan a células nk | |
| EP4509186A3 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| ZA202208710B (en) | Anti-vegf protein compositions and methods for producing the same | |
| EP4417624A3 (en) | Antibodies comprising chimeric constant domains | |
| AU2018260863A1 (en) | Human IgG1 Fc region variants and uses thereof | |
| HK1207575A1 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| MY205418A (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
| EA201692476A1 (ru) | Модифицированные антигенсвязывающие полипептидные конструкции и их применение | |
| JP2016526909A5 (es) | ||
| CU20190087A7 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
| MX377605B (es) | Inmunoglobulina híbrida conteniendo un enlace no-peptidílico. | |
| CO2022010422A2 (es) | Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| IN2014DN10515A (es) | ||
| WO2014144542A3 (en) | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same | |
| WO2016023898A3 (en) | Intracellular antigen binding | |
| EA201892588A1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
| EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| MY198370A (en) | Proteins specific for baff and b7rp1 | |
| WO2011050985A8 (en) | Clonal expansion of b cells | |
| PH12021551150A1 (en) | Transmembrane domain derived from human lrrc24 protein | |
| WO2011015916A3 (en) | Vectors and compounds for expression of recombinant infliximab | |
| AR114285A1 (es) | Constructos de fusión del anticuerpo acoplado a células nk |